U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 19 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexi...
Status:
US Approved Rx (2018)
First approved in 1999

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Dexmedetomide (biologically active dextroisomer of medetomidine) is an alpha2-adrenergic agonist which was approved by FDA for the sedation purposes. Upon administration the drug activates the alpha2 receptors thus inhibiting the release of norepinep...
Status:
US Approved Rx (2015)
First marketed in 1899

Class (Stereo):
CHEMICAL (ABSOLUTE)



The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central se...
Status:
US Previously Marketed
First approved in 1972

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Triclofos is primarily indicated in conditions like Insomnia, and can also be given in adjunctive therapy as an alternative drug of choice in Nausea, vertigo, labyrinthine disorders. It is also used sedate people suffering from anxiety or tension bef...
Status:
US Previously Marketed
First approved in 1960

Class (Stereo):
CHEMICAL (RACEMIC)



Propiomazine is a typical antipsychotic, blocking H1 receptors and is primarily indicated in conditions Insomnia. Propiomazine was also used under brand name largon for the relief of restlessness and apprehension, preoperatively or during surgery. In...
Status:
US Previously Marketed
First approved in 1955

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Ethchlorvynol is used to treat insomnia (trouble in sleeping). It developed by Pfizer in the 1950s. In the United States it was sold by Abbott Laboratories under the tradename Placidyl. Although the exact mechanism of action is unknown, ethchlorvynol...
Status:
US Previously Marketed
First approved in 1951

Class (Stereo):
CHEMICAL (RACEMIC)

Meparfynol is a tertiary hexanol and potent tranquilizer with hypnotic/sedative and anticonvulsant effects and exceptionally low therapeutic index. It was discovered by Bayer in 1913 and was used shortly thereafter for the treatment of insomnia, but ...
Status:
US Previously Marketed
First marketed in 1922

Class (Stereo):
CHEMICAL (ACHIRAL)

Carbromal is containing bromide mild hypnotic that has been used to mild insomnia treatment. Carbromal is one of a number of hypnotics containing bromide, which releases the bromide ion on hydrolysis in the body. It has no advantages over other hypno...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)


Niaprazine is a potent and selective antagonist of 5-HT2A and alpha-1 adrenergic receptors. It was used for the treatment of sleep disturbances in children and was investigated for the treatment of sleep disorders in patients with attention-deficit h...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (RACEMIC)

Apronalide is an acyclic analog of barbiturates. It was used under tradename "Sedormid" as a sedative an hypnotic agent. In 1934 it was discovered that the drug causes thrombocytopenic purpura. Apronalide is still marketed in Japan, where it is used ...

Showing 1 - 10 of 19 results